Welcome to our dedicated page for STERIS plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc President and CEO Daniel A. Carestio reported equity compensation and related tax withholding transactions. He received 23,736 ordinary shares as a grant and 82,740 employee stock options with an exercise price of $230.74 per share, expiring in 2036.
On the same date, 2,369 restricted shares vested, and 995 of those shares were withheld at $209.76 per share to cover employment and tax obligations, rather than sold in the market. After these transactions, he directly owned 72,583 ordinary shares, of which 50,113 were restricted as of June 2, 2026, subject to a multi-year vesting schedule.
STERIS plc senior vice president and CFO Karen L. Burton reported routine equity compensation changes. She received a grant of 5,325 ordinary shares at a stated price of $0.0000 per share and now directly holds 13,464 ordinary shares. Footnotes state that as of June 2, 2026, 10,239 of these ordinary shares are restricted, with restrictions scheduled to lapse in several tranches between June 3, 2026 and June 4, 2029. The filing also records withholding of 66 shares from 225 restricted shares that vested on June 2, 2026 to cover taxes, valued at the NYSE closing market price of $209.76 per share. In addition, Burton received an employee stock option for 18,564 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036, which becomes exercisable in four equal installments from June 2, 2027 through June 3, 2030.
STERIS plc director Pierre Boulud received a grant of 367 Career Restricted Stock Units. These derivative awards were acquired at a price of 0.0000 per unit and are linked to 367 underlying STERIS ordinary shares.
Each Career Restricted Stock Unit represents the right to receive one ordinary share six months after the end of his Board service. The units are fully vested immediately but will only be settled in shares six months after his service on the Board ceases. Following this grant, he holds 367 Career Restricted Stock Units directly.
STERIS plc director Richard C. Breeden reported option exercises and share sales. On 2026-06-02, he exercised options to acquire 3,781 Ordinary Shares at $71.40 per share and sold 1,481 Ordinary Shares in an open-market transaction at a weighted average price of $209.51 per share.
Following these transactions, Breeden directly owned 38,964 Ordinary Shares. A separate entry shows 27,242 Ordinary Shares held indirectly, with footnotes explaining these are owned through Breeden-affiliated investment entities and that he may be deemed an indirect beneficial owner, while disclaiming beneficial ownership of 1,358 of those shares.
STERIS plc senior vice president and general counsel John Adam Zangerle reported a routine share withholding related to restricted stock vesting. On June 1, 2026, 337 ordinary shares were withheld from 1,157 vested restricted shares to cover tax obligations, based on the NYSE closing price that day.
After this tax-withholding disposition, he directly owned 33,332 ordinary shares, including 7,354 restricted shares as of June 1, 2026. The restrictions on these ordinary shares are scheduled to lapse in tranches through June 5, 2028.
STERIS plc vice president and corporate treasurer Renato Tamaro reported a routine tax-withholding share disposition related to vesting equity awards. On June 1, 2026, 81 ordinary shares were withheld from 241 restricted shares that vested to cover required employment and tax obligations, valued at the NYSE closing market price that day.
After this non-market transaction, Tamaro directly held 5,614 ordinary shares, including 1,234 restricted shares as of June 1, 2026. The filing also outlines the schedule on which these remaining restricted shares are set to lapse over 2026–2028.
STERIS plc executive Lindsey McGowan reported routine share updates related to vesting of restricted stock and associated tax withholding. On June 1, 2026, 660 restricted shares vested, and 198 of those shares were withheld to cover taxes, a non-market "F" code tax-withholding disposition.
After these transactions, McGowan directly holds 4,830 ordinary shares, including 3,090 restricted shares subject to future vesting through January 2, 2029. In addition, 255 ordinary share equivalent units are held on her behalf in the STERIS Corporation 401(k) Plan. No open-market purchases or sales were reported.
STERIS plc senior executive Cary L. Majors reported routine equity compensation activity. On June 1, 2026, 2,697 restricted ordinary shares vested, and 768 of those shares were withheld to cover tax obligations, reflected as a tax-withholding disposition rather than an open-market sale.
After this event, Majors directly held 12,659 ordinary shares, including 7,441 restricted shares as of June 1, 2026, with restrictions scheduled to lapse in tranches through 2028. In addition, units representing 67 ordinary share equivalents were held for Majors under the STERIS Corporation 401(k) Plan.
STERIS plc senior executive Julia Madsen reported a routine tax-withholding share disposition tied to vesting equity compensation. On June 1, 2026, 578 restricted shares vested, and 208 of those shares were withheld to cover required taxes based on the NYSE closing market price that day.
After this transaction, she directly holds 10,502 ordinary shares, including 3,425 restricted shares. The restrictions on these ordinary shares are scheduled to lapse in tranches between June 2026 and June 2028.